meta ImmuCell Reports Results from Rotavirus Pivotal Effectiveness Study :: The Bullvine - The Dairy Information You Want To Know When You Need It

ImmuCell Reports Results from Rotavirus Pivotal Effectiveness Study


ImmuCell Corporation (NasdaqCM: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced positive results from its pivotal study to prevent scours (diarrhea) in newborn calves caused by rotavirus.

“Our work to optimize the dosage and product formulation was ultimately responsible for our ability to achieve statistically significant effectiveness versus a placebo control within our rotavirus challenge model,” commented Dr. John W. Zinckgraf, Director of Product Development.

The pivotal effectiveness study, designed to evaluate the Company’s First Defense® milk (colostrum) protein purification technology against a rotavirus challenge, was initiated at Cornell University College of Veterinary Medicine during the second quarter of 2014. The underlying rotavirus vaccine technology, used to generate the specific antibodies, has been licensed exclusively to the Company from Baylor College of Medicine. This product is subject to review and approval by the USDA before any sales can be made.

“This achievement is an important step forward for us extending our First Defense® product line and building on recent product sales growth,” commented Michael F. Brigham, President and CEO. “If approved by the USDA, this would be the first passive antibody product with disease claims against the three leading causes of calf scours, E. coli, coronavirus and rotavirus, providing Immediate Immunity™ to newborn calves.”

After these study results are submitted to the USDA for review, the Company will continue working to complete the other laboratory and manufacturing objectives required for product license approval. This could position the Company to achieve product licensure and market launch in 2016.

About ImmuCell
ImmuCell Corporation’s (NasdaqCM: ICCC) purpose is to create scientifically-proven and practical products that improve animal health and productivity in the dairy and beef industries. ImmuCell has developed products that provide significant, immediate immunity to newborn dairy and beef livestock. The Company has also developed products that address mastitis, the most significant cause of economic loss to the dairy industry. Press releases and other information about the Company are available at our website, (http://www.immucell.com).


Send this to a friend